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Thse capabilities of pentamidine and nine pentamidine analogs to inhibit the development of Toxoplasma
gondii were examined in vitro. Treatment of infected cultures with pentamidine and five of its analogs caused
a significant (P < 0.05) reduction in the numbers of tachyzoites produced. Analogs of pentamidine may be
useful agents in the treatment of toxoplasmosis.
Toxoplasma gondii is an ubiquitous protozoan parasite
that can be an important disease-producing agent in humans
and warm-blooded animals (6). In humans, T. gondii infec-
tions in immunocompetent patients are usually asympto-
matic, whereas infections in immunocompromised patients
or transplacentally infected ants can be life-threatening.
Encephalitis caused by T. jdii has become recognized as
a serious, often fatal, manifestation of the infection seen in
many patients with AIDS (9, 15, 21). Toxoplasmic enceph-
alitis (TE) is probably caused by reactivation of latent tissue
cyst stages (7). Pyrimethamind alone or in combination with
sulfadiazine or trisulfapyrimidines have been the stAndard
treatments for acute toxoplasmosis and TE, although ad-
verse reactions are common (9, 15, 17). Relapse of TE is
common once treatment has been stopped. Additional com-
pounds that do not cause adverse side effects and that have
activity against T. gondii must be discovered and evaluated
for the treatment of acute toxoplasmosis and TE.
Pentamidine and its analogs have been shown to have a
broad spectrum of activity against intracellular and extracel-
lular protozoan parasites as well as Pneumocystis carinii (2,
11, 12, 18-20). Because of this demonstrated effectiveness
against parasitic protozoa, we examined the capabilities of
pentamidine and nine of its analogs to inhibit replication of
the highly pathogenic RH isolate of T. gondii in cell cultures.
Pentamidine and the pentamidine analogs (Table 1) used in
this study were synthesized in the laboratories of Richard R.
Tidwell, Department of Pathology, School of Medicine,
University of North Carolina at Chapel Hill. The methods of
their production and examinations for purity have been
described previously (19). Pentamidine and its analogs were
examined at 100 ,ugIml; compounds found to be toxic at this
concentration were subjected to further study at lower
concentrations (Tables 2 and 3). Pyrimethamine (lot no.
3f0991) and piritrexim (lot no. 87/5089-036; Burroughs Well-
come Co., Research Triangle Park, N.C.) were used at 10
,ug/ml ofmedium in two experiments to ensure that our assay
would identify effective compounds.
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African Green monkey kidney cells (Vero) (ATTC CCL
81; American Type Culture Collection, Rockville, Md.) were
grown to monolayers in 25-cm2 plastic tissue culture flasks in
RPMI 1640 medium containing 10% (vol/vol) fetal bovine
serum, 100 U of penicillin G per ml, 100 ,ug of dihydrostrep-
tomycin (GIBCO, Grand Island, N.Y.) per ml, and 5 x 10-2
mM 2-mercaptoethanol (Sigma Chemical Co., St. Louis,
Mo.). Cell cultures were maintained in an identical medium,
but the concentration of fetal boyine serum was lowered to
2% (vol/vol). Cell cultures were incubated at 37°C in a 95%
air-5% CO2 atmosphere.
Tachyzoites of the RH isolate of T. gondii are maintained
in the laboratories of David S. Lindsay and Byron L.
Blagburn, Department of Pathobiology, Auburn University,
by serial passage in infected Vero cell cultures. Tachyzoites
were collected for inoculation of cell cultures by first remov-
ing the cell culture medium and replacing it with fresh
maintenance medium. The Vero cells were then scraped off
the plastic growth surface into the medium, and the suspen-
sion was forced through a syringe equipped with a 27-gauge
needle to rupture most infected Vero cells. The free tachy-
zoites were separated from intact cells and most cellular
debris by filtration through a sterile 3-,um-pore-size polycar-
bonate filter (Nuclepore Corp., Pleasanton, Calif.). The
numbers of tachyzoites present were determined by count-
ing them in a hemacytometer, and the volume of inoculum
was adjusted so that 1 ml contained 2 x 105 tachyzoites. For
each treatment, four 25-cm2 flasks were each inoculated with
2 x 105 tachyzoites. Two hours postinoculation (p.i.), the
tachyzoite inoculum was removed and replaced with test
compounds in maintenance medium. Pentamidine, pentami-
dine analogs, and piritrexim were solubilized in deionized
water and diluted in maintenance medium, whereas py-
rimethamine was solubilized in 100% ethanol. Controls
received maintenance medium to which an equal amount of
deionized water was added. Media were removed from the
infected cells 4 to 4.5 days p.i., the volume was recorded,
and the numbers of tachyzoites present were determined by
counting them in a hemacytometer. The total number of
tachyzoites present in each flask was determined by multi-
plying the volume of the medium by the numbers of tachy-
zoites present (mean of six counts per flask) per milliliter of
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no. Position Y Compound namen X
1 3 -OCH3 Am 4 1,3-Di(4-amindino-2-methoxyphenoxy)propane
2 3 -H Im 4 1,3-Di(4-imidazolinophenoxy)propane
3 4 -OCH3 Im 4 1,4-Di(4-imidazolino-2-methoxyphenoxy)butane
4 4 -H Am 4 1,4-Di(4-amidinophenoxy)butane
5 3 -OCH3 Im 4 1,3-Di(4-imidazolino-2-methoxyphenoxy)propane [DIMP]
6 3 -OCH3 Im 5 1,3-Di(5-imidazolino-2-methoxyphenoxy)propane
7 5 -OCH3 Im 4 1,5-Di(4-imidazolino-2-methoxyphenoxy)pentane
8 4 -OCH3 Am 4 1,4-Di(4-amidino-2-methoxyphenoxy)butane [dimethoxybutane]
9 6 -H Am 4 1,6-Di(4-amidinophenoxy)hexane [hexamidine]





medium. Mean total tachyzoite production was analyzed by
a nonparametric one-tailed Mann-Whitney test. Designation
of significant differences in all experiments was based on a
cutoff ofP < 0.05. The percent reduction in tachyzoites was
calculated by subtracting the mean treated values from the
mean control value, dividing this numerator by the mean
control value, and multiplying the product by 100. Eight
experiments were conducted (Tables 2 and 3).
Pentamidine and compounds 3, 6, 7, 8, and 9 reduced the
numbers of T. gondii RH tachyzoites in cell cultures (Tables
TABLE 2. Activities of pentamidine analogs against T. gondii
in Vero cell cultures'
Total no. of
Expt no. Compoundb tachyzoites/ flask % Reductione
(mean ± SD [1041)
1 Control 597 ± 166 NA
1 (100) 1,088 ± 408 0
2 (100) 950 ± 287 0
3 (100) 45 ± 11 92.5*
2 Control 672 ± 173 NA
5 (100) 1,325 ± 633 0
3 Control 1,367 ± 141 NA
4 (50) 1,065 ± 233 22.1
6 (100) 649 ± 304 52.5*
4 Control 479 + 120 NA
7 (100) 28 ± 13 94.2*
8 (100) 102 ± 51 78.7*
Pyrimethamine (10) 3 + 3 99.4*
a Pentamidine and compound 9 were toxic at 100 and 50 ,ug/ml, and
compound 4 was toxic at 100 ,ug/ml.
b Control cultures received no drug treatment and treated cultures received
treatment at the concentration (in micrograms per milliliter) given in paren-
theses.
c NA, not applicable; negative percent reductions are expressed as 0; *,
significant reduction in the number of tachyzoites per flask compared with that
in control flasks (P < 0.05).
2 and 3). Because compounds 3, 7, and 8 appeared to be
highly effective at 100 p.g/ml, additional doses were exam-
ined (Table 3). Compounds 1, 2, 4, and 5 had no significant
effects on tachyzoite production. Pentamidine and com-
pound 9 were toxic at 100 and 50 ,ug/ml, and compound 4 was
toxic at 100 ,ug/ml for Vero cell cultures. These compounds
were considered toxic because many of the Vero cells
became rounded and detached from the plastic growth
surface by 1 to 3 days p.i. in these flasks, whereas Vero cells
in flasks infected with T. gondii and not treated did not
exhibit these cytopathic changes. When pentamidine was
evaluated at 25 and 10 ,ug/ml (Table 3), significant effects on
TABLE 3. Dosage evaluations of pentamidine and compounds 3,
7, 8, and 9 against T. gondii in Vero cell cultures
Expt no. Dose Total no. of
(cornpound) Dose/ml) tachyzoites/flask % Reductionb(compond) (g/mi) (mean ± SD [WI~)
5 (compound 3) Control 1,093 ± 108 NA
10 859 + 268 21.4
50 176 ± 97 83.9*
6 (pentamidine) Control 579 + 116 NA
10 230 ± 56 60.3*
25 182 ± 95 68.6*
7 Control 316 ± 157 NA
Compound 7 10 423 ± 85 0
50 62 ± 23 80.4*
Compound 8 10 809 ± 234 0
50 132 ± 66 58.2
8 Control 506 ± 125 NA
Compound 9 10 92 ± 62 81.8*
Piritrexim 10 1 ± 1 99.8*
"Control cultures received no drug treatment.
b NA, not applicable; negative percent reductions are expressed as 0; *,
significant reduction in the number of tachyzoites per flask compared with that






tachyzoite replication were observed. Compound 9 was
effective when it was examined at 10 ,ug/ml (Table 3).
Pyrimethamine and piritrexim both significantly inhibited
tachyzoite replication in our assay at a concentration of 10
,ug/ml (Tables 2 and 3).
Many antimicrobial agents have been evaluated for their
effectiveness against T. gondii; these include dihydrofolate
reductase inhibitors, macrolide antibiotics, polyether iono-
phorous antibiotics, sulfonamides, 1,2,4-trioxanes, hydroxy-
naphthoquinones, and purine analogs (1, 3-5, 8, 10, 13, 14,
16, 17). However, the present study appears to be the first to
evaluate the effectiveness of pentamidine and some of its
analogs against T. gondii.
The present study demonstrated that pentamidine and five
of its analogs are effective in inhibiting replication of the RH
isolate of T. gondii in cell cultures and suggests that other
analogs of pentamidine may also be effective against the
parasite. Future studies should focus on evaluation of these
additional analogs. Additionally, studies must be conducted
to determine whether synergistic effects are observed when
these compounds are administered with other effective com-
pounds.
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